BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes; obesity A fusion protein comprising FGF21 and GLP-1 analogs linked by an elastin-like polypeptide could treat diabetes and obesity. In HEK cells, the fusion protein agonized the FGF21 receptor complex...
BioCentury | Sep 16, 2020

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...
BioCentury | Sep 2, 2020

NASH therapy from Novartis adds 15th program to Boston Pharmaceuticals’ pipeline

With this week’s addition of a NASH therapy from Novartis, Boston Pharmaceuticals is well on its way to the goal set by founders Christopher Viehbacher and Robert Armstrong when they launched the in-licensing play with $600 million...
BioCentury | Aug 26, 2020

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

The presence of half a dozen crossover investors in Kinnate’s $98 million series C round suggests an IPO could be the next financing for the precision oncology company.  If it does go public this year before...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...
BioCentury | Jul 16, 2020

Relay’s IPO among the year’s largest for a biotech as others wait in wings

In a year when most new biotech listings have surpassed expectations, Relay’s upsized $400 million IPO is the second-largest yet for a therapeutics developer in 2020. The clinical developer of precision oncology therapies posted a...
BioCentury | Jul 14, 2020

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jul 7, 2020

Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

In its latest cross-border in-licensing deal, Zai gained territorial rights to yet another targeted cancer therapy via a deal with Turning Point for repotrectinib, which is in a pivotal trial that could lead to approvals...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

Akero’s biopsy data is the positive news the NASH field needed after FDA declined to approve what would have been the first drug for the indication earlier this week. Akero Therapeutics Inc. (NASDAQ:AKRO) rose $8.45...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
Items per page:
1 - 10 of 898